Research Article

Diabetes Increases Risk of Cardiovascular Events in Patients Receiving Permanent Pacemaker: A Propensity Score-Matched Cohort Study

Huang-Chung Chen, Wen-Hao Liu, Chien-Hao Tseng, Yung-Lung Chen, Wei-Chieh Lee, Yen-Nan Fang, Shaur-Zheng Chong, and Mien-Cheng Chen

Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taiwan

Correspondence should be addressed to Mien-Cheng Chen; chenmien@ms76.hinet.net

Received 6 January 2022; Revised 27 February 2022; Accepted 5 March 2022; Published 28 March 2022

Academic Editor: Krzysztof Zmudka

Copyright © 2022 Huang-Chung Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Type 2 diabetes was associated with a higher risk for permanent pacemaker (PPM) treatment. The difference in cardiovascular outcomes between patients with and without diabetes receiving PPM treatment remains unexplored. Method. Between January 2003 and December 2017, 1742 patients receiving naïve PPM treatment comprised this retrospective cohort study and were categorized into two groups by the diagnosis of diabetes: group with diabetes (n = 632, 36.3%) and group without diabetes (n = 1110, 63.7%). The primary outcome was cardiovascular events including heart failure (HF) hospitalization and acute myocardial infarction (AMI). The secondary outcomes of this study included pacemaker infection, pacing-induced cardiomyopathy, cerebrovascular accident, cardiovascular mortality, and all-cause mortality. Propensity score matching (PSM) was applied to reduce selection bias between the study groups. Result. During a mean follow-up period of 7.8 ± 4.8 years, 264 patients had a cardiovascular event. Before PSM, the incidence of cardiovascular events was higher in patients with diabetes compared to patients without diabetes (19.8% vs. 12.5%, P < 0.001), and the incidences of pacing-induced cardiomyopathy, cardiovascular mortality, and all-cause mortality were all higher in patients with diabetes compared to patients without diabetes. After PSM, the incidence of cardiovascular events was higher in patients with diabetes compared to patients without diabetes (18.8% vs. 12.3%, P = 0.015). The incidence of HF hospitalization was higher in patients with diabetes compared to patients without diabetes (15.3% vs. 10.2%, P = 0.037), whereas the incidence of AMI did not differ between the two groups. Moreover, after PSM, patients with diabetes had higher cumulative incidences of pacing-induced cardiomyopathy and all-cause mortality compared to patients without diabetes. Conclusions. The prevalence of diabetes was over one-third of naïve PPM recipients of this cohort, and diabetes increased the risk of cardiovascular events in PPM recipients, especially for HF hospitalization.

1. Introduction

Diabetes mellitus is a serious chronic disease with an imperative influence on the health of a human being in the world. Owing to the aging population, economic development, and change of lifestyle, the growth in global and regional prevalences of type 2 diabetes markedly increased [1–4]. The number of patients with type 2 diabetes had doubled during the past two decades, and half of people with diabetes are not even aware that they have diabetes [1, 4]. Diabetes is a well-known risk factor for cardiovascular events, such as acute myocardial infarction (AMI) and heart failure (HF) [5, 6]. Previous studies demonstrated that lethal tachyarrhythmia occurs commonly in patients with diabetes, possibly related to myocardial ischemia and sympathoadrenal activation in response to hypoglycemia [7, 8]. On the other hand, an association between bradyarrhythmia and diabetes has also been reported, which is possibly caused by microangiopathy and
increased cholinergic sensitivity [9–11]. From a national diabetes registry study, Rautio et al. reported that type 2 diabetes was associated with a 1.6-fold higher risk for permanent pacemaker (PPM) treatment after adjustments for age, sex, and other factors [12]. However, the difference in cardiovascular outcomes between patients with and without type 2 diabetes receiving PPM treatment remains unexplored. Moreover, type 2 diabetes as an independent risk factor for cardiovascular events in pacemaker recipients remains unexplored. Accordingly, we conducted this retrospective cohort study to investigate and compare the clinical outcomes between patients with and without type 2 diabetes receiving PPM treatment after propensity score matching (PSM). Moreover, this study is also aimed at identifying whether type 2 diabetes increases risk of cardiovascular events in PPM recipients.

2. Methods

2.1. Study Cohort. This retrospective cohort study enrolled 2706 consecutive patients receiving cardiac implantable electronic device implantation in our hospital between January 2003 and December 2017. A total of 964 patients, including 191 patients with implantable intracardiac defibrillators, 78 patients with cardiac resynchronization therapy, and 695 patients with replacement of generator, were excluded (Figure 1). His-Purkinje conduction system pacing was also excluded in this study because pacing leads for His-Purkinje conduction system pacing were not available in our institute between January 2003 and December 2017. Finally, 1742 patients receiving single ventricular or dual chamber PPMs comprised this retrospective cohort study population and were categorized into two groups by the presence or absence of diagnosis of type 2 diabetes at the time of PPM implantation: group with diabetes (n = 632, 36.3%) and group without diabetes (n = 1110, 63.7%) (Figure 1). The standard protocol for PPM implantation in our center had been described in our previous study [13], mainly right ventricular lead placed at the right ventricular outflow tract or high septum.

2.2. Definitions. Based on recommendations from the American Diabetes Association [14], diabetes was defined as prescription for oral antidiabetic drugs or insulin, or HbA1c ≥ 6.5% (48 mmol/mol), or fasting plasma glucose level ≥ 126 mg/dL (7.0 mmol/L), or a random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) with classic symptoms of hyperglycemia or hyperglycemic crisis during hospitalization for PPM implantation. According to the guidelines of Kidney Disease: Improving Global Outcomes [15], microalbuminuria was defined as at least two positive results obtained within 1 year and was defined as an albumin-to-creatinine ratio of 30–300 mg/g (3–30 mg/mmol); macroalbuminuria was defined as an albumin-to-creatinine ratio ≥300 mg/g (>30 mg/mmol). Estimated glomerular filtration rate (eGFR) was estimated from the creatinine value and calculated using the Chronic Kidney Disease Epidemiology Collaboration equation [16]. Chronic kidney disease (CKD) was defined as eGFR lower than 60 mL/min/1.73 m² without renal replacement therapy and end-stage renal disease as the need for peritoneal dialysis, hemodialysis, or renal transplantation. Hyperlipidemia was defined as total cholesterol ≥ 240 mg/dL, low-density lipoprotein ≥ 150 mg/dL, or triglyceride ≥ 200 mg/dL, or on lipid-lowering medications [17]. Valvular heart disease was defined as moderate to severe regurgitation or stenosis of aortic, mitral, or tricuspid valves. Cardiovascular surgery included coronary artery bypass graft and valvular surgery. Chronic lung disease was defined as a history of asthma, chronic obstructive pulmonary disease, or pulmonary fibrosis.

2.3. Clinical Outcomes. The primary outcome of this study was cardiovascular events of patients after PPM implantation. Cardiovascular events included hospitalization related to HF event of New York Heart Association functional class of III-IV, or AMI. The secondary outcomes of this study included pacemaker infection, pacing-induced cardiomyopathy, cerebrovascular accident, cardiovascular mortality, and all-cause mortality. Pacemaker infection was divided into major and minor infections according to clinical presentation and management. Major infection was defined as any presentation of (1) erosive wound, (2) bloodstream infection, (3) pacemaker-related endocarditis, or (4) need for surgical removal. Minor infection was defined as (1) the local inflammatory signs including erythema, warmth, fluctuate, or tenderness at the pocket sites, (2) presentation of any discharge, or (3) wound dehiscence [18]. Pacing-induced cardiomyopathy was defined as a ≥10% decrease of the baseline left ventricular ejection fraction (LVEF) with a resultant LVEF < 50%. Cerebrovascular accident was defined as an episode of transient ischemic attack, ischemic stroke, intracranial hemorrhage, or any incident finding by images, including brain computed tomography or magnetic resonance imaging after PPM implantation. Cardiovascular mortality was defined as death from AMI, HF, refractory ventricular arrhythmias, or cardiac arrest. After PPM implantation, patients were followed up monthly for the first three months and then every three to six months until clinical outcomes of interest, death, loss to follow up, or the latest date in the dataset (31 December, 2020), whichever came first.

2.4. Study Covariates. Baseline variables considered in the analyses included patient’s age, sex, body mass index, and comorbidities associated with clinical outcomes including hypertension, hyperlipidemia, coronary artery disease, HF, atrial fibrillation, valvular heart disease, CKD, history of cardiovascular surgery, cancer, and chronic lung disease. The prescription for medication, such as beta-blocker, antihypertensive drugs, diuretic agents, and lipid-lowering agents, laboratory data including hemoglobin and serum creatinine, the indication and lead number of PPM, and baseline and pacing QRS duration were also obtained.

2.5. Statistical Analysis. Continuous variables are expressed as a mean ± standard deviation or percentages. The clinical characteristics of the study groups were compared using the independent t-test for continuous variables and Chi-
square test or Fisher’s exact test for categorical variables. PSM was applied to make the covariates balanced between the study groups. The propensity score was calculated using multivariable logistic regression where the study group was regressed on all of the covariates listed in Table 1, except eGFR, HbA1c, low-density lipoprotein, high-density lipoprotein, triglyceride, albuminuria, and preprocedural echocardiographic data. Using NCSS 10 Statistical Software (LLC, Kaysville, Utah, USA), the greedy method was used for matching at a 1:1 ratio between the study groups with a caliper width 0.2-fold of the standard deviation of the logit of the propensity score. The quality of matching was checked using the absolute value of standardized difference between the groups, where a value <0.1 was considered negligible difference [19]. The incidences of all clinical outcomes during long-term follow-up were expressed with Kaplan-Meier survival curves and compared by log-rank test. The significance of each variable in predicting all clinical outcomes was tested using the Cox proportional hazards model, analyzed with forward option. A two-sided P value <0.05 was considered statistically significant. SPSS for Windows (version 22.0; SPSS Inc., Chicago, IL, USA) was used to perform the statistical analysis.

3. Results

3.1. Baseline Characteristics of the Study Patients with and without Type 2 Diabetes. Table 1 lists the clinical characteristics of the study patients before and after PSM. Before PSM, the mean age of the patient population was 73 ± 11 years and 48.6% of the study patients were male. There were 632 (36.3%) patients with diabetes, which were under diet control alone (12.8%), oral antidiabetic drugs (74.7%), or insulin-based therapy (12.5%), and 1110 (63.7%) patients without diabetes (Figure 1). The patients with diabetes had more patients with overweight and higher prevalence of hypertension, hyperlipidemia, coronary artery disease, CKD, and end-stage renal disease (all P < 0.001) compared to the patients without diabetes. Patients with diabetes also had a higher prevalence of history of HF (P = 0.033), atrial fibrillation (P = 0.007), and cerebrovascular accident (P = 0.028) compared to patients without diabetes. Patients with diabetes had more prescription for beta-blocker (P = 0.001), angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (ACEi/ARB), diuretic agents, and statin (all P < 0.001). Patients with diabetes had higher serum creatinine, HbA1c, and triglyceride and a higher prevalence of albuminuria including microalbuminuria and macroalbuminuria (all P < 0.001) compared to patients without diabetes. Patients with diabetes had lower levels of hemoglobin, eGFR, low-density lipoprotein, and high-density lipoprotein (all P < 0.001) compared to patients without diabetes. Patients with diabetes had a higher prevalence of atrioventricular block (P = 0.001), larger number of PPM leads (P = 0.025), wider baseline and pacing QRS durations (P = 0.037 and P = 0.019, respectively), and higher percentage of right ventricular pacing (P < 0.001) compared to patients without diabetes. Patients with diabetes had larger preprocedural left atrial size (P = 0.010) and LV end-diastolic volume (P = 0.049) and lower preprocedural LVEF (P = 0.042) compared to patients without diabetes (Table 1).

In the study cohort after 1:1 PSM, 373 pairs with and without diabetes were analyzed. The baseline characteristics were balanced in the matched groups (Table 1). After PSM, the matched patients with diabetes still had lower low-density lipoprotein (P = 0.001) and high-density lipoprotein (P = 0.005) and higher triglyceride (P = 0.049) levels as well as higher prevalence of albuminuria (P < 0.001) compared to the matched patients without diabetes (Table 1).

3.2. Clinical Outcomes of the Study Patients with and without Type 2 Diabetes before and after PSM. During a mean
| Baseline characteristics | Before matching Diabetes (n = 632; 36.3%) | After matching Diabetes (n = 373) | P value | SMD | Before matching Nondiabetes (n = 1110; 63.7%) | After matching Nondiabetes (n = 373) | P value | SMD |
|-------------------------|------------------------------------------|----------------------------------|--------|-----|------------------------------------------|----------------------------------|--------|-----|
| Age, (years)            | 73 ± 9                                   | 74 ± 9                           | 0.080  | 0.080 | 75 ± 11                                   | 0.232                           | 0.088  |
| Male                    | 300 (47.5)                               | 185 (49.6)                       | <0.001 | N/A  | 25 (47.5)                                 | 26 (49.6)                       | <0.001 | N/A |
| Body mass index, (kg/m²) | 26 ± 4                                   | 25 ± 4                           | <0.001 | N/A  | 25 ± 4                                    | 25 ± 4                           | <0.001 | N/A |
| Overweight (>30 kg/m²)  | 59 (9.3)                                 | 22 (5.9)                         | <0.001 | 0.187 | 26 (9.3)                                  | 7.0)                            | <0.001 | 0.044|
| Underweight (<20 kg/m²) | 21 (3.3)                                 | 17 (4.6)                         | <0.001 | 0.248 | 21 (3.3)                                  | 5.6)                            | <0.001 | 0.049|
| Hypertension            | 524 (82.9)                               | 296 (79.4)                       | <0.001 | 0.433 | 295 (82.9)                                | 79.1)                           | <0.001 | 0.928|
| Hyperlipidemia          | 319 (50.5)                               | 160 (42.9)                       | <0.001 | 0.567 | 163 (50.5)                                | 43.7)                           | <0.001 | 0.825|
| Coronary artery disease | 187 (29.6)                               | 79 (21.2)                        | <0.001 | 0.368 | 74 (29.6)                                 | 19.8)                           | <0.001 | 0.650|
| Heart failure history   | 130 (20.6)                               | 63 (16.9)                        | <0.001 | 0.092 | 63 (20.6)                                 | 16.9)                           | <0.001 | 1.000|
| Valvular heart disease† | 27 (4.3)                                 | 19 (5.1)                         | 0.101  | 0.081 | 21 (4.3)                                  | 5.6)                            | 0.714  | 0.027|
| Atrial fibrillation     | 219 (34.7)                               | 143 (38.3)                       | <0.001 | 0.188 | 147 (34.7)                                | 39.4)                           | <0.001 | 0.764|
| Cerebrovascular accident| 142 (22.5)                               | 75 (20.1)                        | 0.028  | 0.077 | 75 (22.5)                                 | 20.1)                           | 1.000  | <0.001|
| Chronic kidney disease‡ | 291 (46.0)                               | 170 (45.3)                       | <0.001 | 0.210 | 169 (46.0)                                | 45.3)                           | 0.941  | 0.005|
| End-stage renal disease§| 68 (10.8)                                | 20 (5.4)                         | <0.001 | 0.254 | 20 (10.8)                                 | 5.4)                            | 1.000  | <0.001|
| Chronic lung disease†   | 27 (4.3)                                 | 14 (4.3)                         | 0.572  | 0.073 | 16 (4.3)                                  | 4.3)                            | 0.709  | 0.027|
| History of cardiovascular surgery | 31 (4.9) | 17 (4.6) | 0.963  | 0.014 | 16 (4.3) | 4.3) | 0.859 | 0.013|
| History of cancer       | 74 (11.7)                                | 45 (12.1)                        | 0.607  | 0.055 | 51 (11.7)                                 | 13.7)                           | 0.512  | 0.048|
| Prescription for drugs  |                                         |                                 |        |      |                                         |                                 |        |      |
| Beta-blocker            | 121 (19.1)                               | 64 (17.2)                        | 0.001  | 0.177 | 51 (19.1)                                 | 17.2)                           | 0.187  | 0.097|
| ACEi/ARB            | 370 (58.5)                               | 212 (56.8)                       | <0.001 | 0.297 | 203 (58.5)                                | 56.8)                           | 0.507  | 0.049|
| Diuretic agents         | 212 (33.5)                               | 113 (30.3)                       | <0.001 | 0.265 | 114 (33.5)                                | 30.3)                           | 0.937  | 0.006|
| Statin                  | 193 (30.5)                               | 89 (23.9)                        | <0.001 | 0.439 | 95 (30.5)                                 | 23.9)                           | 0.610  | 0.037|
| Diabetic therapy        |                                         |                                 |        |      |                                         |                                 |        |      |
| Diet control alone      | 81 (12.8)                                | 59 (15.8)                        |        |      |                                         | 59 (12.8)                       |        |      |
| Oral antidiabetic drugs | 472 (74.7)                               | 282 (75.6)                       |        |      |                                         | 282 (74.7)                      |        |      |
| Insulin-based therapy   | 79 (12.5)                                | 32 (8.6)                         |        |      |                                         | 32 (8.6)                        |        |      |
| Laboratory data         |                                         |                                 |        |      |                                         |                                 |        |      |
| Hemoglobin, (g/dL)      | 12.0 ± 1.9                               | 12.3 ± 1.9                       | <0.001 | 0.409 | 12.2 ± 1.9                                | 1.9 | 0.754 | 0.023|
| Serum creatinine, (mg/dL)| 2.0 ± 2.1                                | 1.7 ± 1.8                       | <0.001 | 0.301 | 1.6 ± 2.0                                  | 2.0 | 0.732 | 0.025|
| eGFR, (mL/min/1.73m²)   | 54 ± 30                                  | 58 ± 28                         | <0.001 | N/A  | 61 ± 29                                    | N/A | 0.171 | N/A |
| HbA1c                   | 54 ± 10                                  | 52 ± 8                          | <0.001 | N/A  | 39 ± 3                                     | N/A | <0.001 | N/A |
| %                       | 7.1 ± 1.3                                | 6.9 ± 1.1                       | <0.001 | 0.439 | 5.7 ± 0.4                                  | 4.3) | <0.001 | N/A |
Table 1: Continued.

|                     | Before matching | After matching |
|---------------------|-----------------|----------------|
|                     | Diabetes (n = 632; 36.3%) | Nondiabetes (n = 1110; 63.7%) | P value | SMD | Diabetes (n = 373) | Nondiabetes (n = 373) | P value | SMD |
| LDL, (mg/dL)        | 90 ± 34         | 101 ± 34       | <0.001 N/A | 89 ± 33 | 101 ± 39       | 0.001 N/A | 0.005 N/A |
| HDL, (mg/dL)        | 47 ± 13         | 53 ± 16        | <0.001 N/A | 48 ± 13 | 52 ± 15        | <0.001 N/A | N/A |
| Triglyceride, (mg/dL) | 128 ± 87       | 103 ± 55       | <0.001 N/A | 124 ± 99 | 109 ± 59       | 0.049 N/A | N/A |
| Albuminuria, (mg/g) | 141 (22.3)      | 70 (6.3)       | <0.001 N/A | 89 (23.9) | 36 (9.7)       | <0.001 N/A | N/A |
| Microalbuminuria    | 91 (14.4)       | 53 (4.8)       | <0.001 N/A | 58 (15.5) | 25 (6.7)       | <0.001 N/A | N/A |
| Macroalbuminuria    | 50 (7.9)        | 17 (1.5)       | <0.001 N/A | 31 (8.3) | 11 (2.9)       | 0.001 N/A | N/A |

Electrocardiographic and pacemaker data

|                     |                  |                |                |                  |                |                |
|---------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|
| Patients with atrioventricular block | 278 (44.0) | 397 (35.8) | 0.001 0.282 | 154 (41.4) | 156 (41.8) | 0.882 0.011 |
| Number of pacemaker lead | 1.9 ± 3.8 | 1.8 ± 3.8 | 0.025 0.107 | 1.9 ± 0.3 | 1.9 ± 0.3 | 0.661 0.034 |
| Baseline QRS duration (ms) | 103 ± 25 | 101 ± 24 | 0.037 0.127 | 103 ± 24 | 103 ± 25 | 0.928 0.007 |
| Pacing QRS duration (ms) | 167 ± 19 | 164 ± 19 | 0.019 0.154 | 165 ± 17 | 164 ± 18 | 0.180 0.098 |
| Percentage of right ventricular pacing (%) | 64 ± 42 (range: 0-100) | 52 ± 44 (range: 0-100) | <0.001 N/A | 62 ± 42 (range: 0-100) | 54 ± 42 (range: 0-100) | 0.075 N/A |
| Percentage with right ventricular pacing >40% (%) | 146 (23.1) | 267 (24.1) | 0.677 N/A | 95 (25.5) | 89 (23.9) | 0.610 N/A |

Pre-procedural echocardiographic data

|                     |                  |                |                |                  |                |                |
|---------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|
| LA size, (mm)       | 39 ± 7          | 38 ± 8         | 0.010 N/A | 39 ± 7          | 39 ± 8         | 0.895 N/A |
| LVEDV, (ml)         | 114 ± 35        | 110 ± 38       | 0.049 N/A | 114 ± 33        | 113 ± 39       | 0.676 N/A |
| LVESV, (ml)         | 39 ± 23         | 37 ± 38        | 0.065 N/A | 38 ± 21         | 38 ± 24        | 0.898 N/A |
| LVEF, (%)           | 67 ± 12         | 68 ± 11        | 0.042 N/A | 68 ± 11         | 67 ± 12        | 0.876 N/A |

*Data are presented as mean ± SD or number (%) of patients. †Defined as moderate to severe regurgitation or stenosis of aortic, mitral, or tricuspid valves. ‡Defined as eGFR lower than 60 mL/min/1.73 m² without renal replacement therapy. §Defined as the need for peritoneal dialysis, hemodialysis, or renal transplantation. ||Defined as the history of asthma, or chronic obstructive pulmonary disease, or pulmonary fibrosis. ACEi/ARB: angiotensin-converting enzyme inhibitors/angiotensin receptor blocker; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; HDL: high-density lipoprotein; LA: left atrium; LDL: low-density lipoprotein; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic volume; N/A: not applicable; SMD: standardized mean difference.
follow-up period of 7.8 ± 4.8 years, before PSM, the incidence of cardiovascular events was higher in patients with diabetes compared to patients without diabetes (19.8% vs. 12.5%; hazard ratio (HR) = 2.06; 95% confidence interval (CI), 1.61-2.62; \( P < 0.001 \)) (Table 2), and the incidences of pacing-induced cardiomyopathy (16.6% vs. 9.7%; HR = 2.24; 95% CI, 1.71-2.93; \( P < 0.001 \)), cerebrovascular accident (13.1% vs. 12.7%; HR = 1.32; 95% CI, 1.00-1.73; \( P = 0.047 \)), cardiovascular mortality (8.9% vs. 6.1%; HR = 1.81; 95% CI, 1.27-2.58; \( P = 0.001 \)), and all-cause mortality (29.4% vs. 21.4%; HR = 1.75; 95% CI, 1.44-2.12; \( P < 0.001 \)) were also observed in patients with diabetes compared to patients without diabetes before and after PSM (Table 2). The incidences of pacemaker infection including major and minor infections did not differ between the two groups (Table 2). After PSM, the incidence of cardiovascular events was still higher in patients with diabetes compared to patients without diabetes (18.8% vs. 12.3%; HR = 1.82; 95% CI, 1.25-2.63; \( P = 0.002 \)) (Table 2). Patients with diabetes had a higher incidence of HF hospitalization compared to patients without diabetes (18.8% vs. 12.3%; HR = 1.62; 95% CI, 1.11-2.36; \( P = 0.013 \)) and all-cause mortality (25.5% vs. 20.6%; HR = 1.41; 95% CI, 1.05-1.92; \( P = 0.023 \)) compared to patients without diabetes (Table 2). However, after PSM, the incidences of pacemaker infection, cerebrovascular accident, and cardiovascular mortality did not differ between the two groups.

The Kaplan–Meier curve analysis for cardiovascular events showed that patients with diabetes had a higher cumulative incidence of cardiovascular events compared to patients without diabetes before and after PSM (log-rank test, \( P < 0.001 \) and \( P = 0.001 \), respectively) (Figures 2(a) and 2(d)). Moreover, patients with diabetes had a higher cumulative incidence of HF hospitalization compared to patients without diabetes before and after PSM (log-rank test, \( P < 0.001 \) and \( P = 0.005 \), respectively) (Figures 2(b) and 2(e)). However, the cumulative incidence of AMI did not differ between the two groups before and after PSM (Figures 2(c) and 2(f)). The Kaplan–Meier curve analysis for pacing-induced cardiomyopathy showed that patients with diabetes had a higher cumulative incidence of pacing-induced cardiomyopathy compared to patients without diabetes before and after PSM (log-rank test, \( P < 0.001 \) and \( P = 0.012 \), respectively) (Figures 3(a) and 3(d)). Furthermore, patients with diabetes had a higher cumulative incidence of all-cause mortality compared to the patients without diabetes before and after PSM (log-rank test, \( P < 0.001 \) and \( P = 0.022 \), respectively) (Figures 3(c) and 3(f)). However, the cumulative incidence of cardiovascular mortality did not differ between the two groups after PSM (Figure 3(e)).

4. Discussion

In this cohort study, the prevalence of diabetes was 36.3%, over one-third of naïve PPM recipients. During a mean follow-up of 7.8 ± 4.8 years, after PSM, the incidences of cardiovascular events and HF hospitalization were significantly higher in patients with diabetes compared to patients without diabetes. Moreover, the cumulative incidences of cardiovascular events and HF hospitalization were significantly higher in the matched group with diabetes compared to the matched group without diabetes. Furthermore, patients with diabetes had a higher cumulative incidence of pacing-induced cardiomyopathy and all-cause mortality compared to patients without diabetes before and after PSM.
The prevalence of diabetes in patients receiving pacemakers. The global prevalence of diabetes is rising from 8% in 1980 to 9.3% in 2019 and is estimated to be 10.9% by 2045, which may be attributable to population growth and ageing [1, 2]. In the Taiwanese population, the annual prevalence of diabetes increased significantly from 5.8% in 2000 to 8.3% in 2007, especially in the subgroup of men, age ≥ 80 years, and individuals residing in aging society areas [3]. In the elderly aged ≥ 65 years, around 15%-20% of people live with diabetes [1, 20]. In this study, PPM recipients were aged and the prevalence of diabetes was 36.3%, which was higher than general population [1-3, 20] and was compatible with previous data of PPM recipients [21, 22]. Moreover, similar to other reports [1-3, 20], the trend in the prevalence of diabetes in this study also increased from 28.8% (between 2003 and 2007) and 36.0% (between 2008 and 2012) to 41.4% (between 2013 and 2017).

Prior study reported that diabetes was possibly associated with sinus nodal dysfunction and cardiac conduction abnormalities [9-11, 23]. Movahed et al. reported that the incidence of complete atrioventricular block in patients with diabetes was 1.1%, which was 3-fold increased risk compared to patients without diabetes [11]. Patients with diabetes of this study had a higher prevalence of atrioventricular block compared to patients without diabetes (44.0% vs. 35.8%, P = 0.001) (Table 1), similar to other reports [10-12]. From a national diabetes registry study, Rautio et al. reported that diabetes increased 1.6-fold risk for implantation of PPM after adjustments for age, sex, and other factors [12]. Therefore, type 2 diabetes is a risk factor for PPM implantation and vigilant follow-up for bradycardia in patients with diabetes is necessary.

4.2. Heart Failure Hospitalization in Patients with Diabetes after Pacemaker Implantation. The prevalence of diabetes in HF patients is around 20%, and diabetes increased 1.74-fold risk and 1.95-fold risk of HF in men and women, respectively [6, 24]. In the Reduction of Atherothrombosis for Continued Health (REACH) Registry, diabetes was also associated with a 33% greater risk of HF hospitalization [25]. The reasons for increasing risk of HF in patients with diabetes included combined comorbidities, such as hypertension, acceleration of the development of coronary atherosclerosis, and diabetic cardiomyopathy, which was related to microangiopathy, metabolic factors, or myocardial fibrosis [24]. Moreover, a study using the National Readmission Database showed that the most common cause for readmission in PPM recipients was HF hospitalization [26]. Similar
to general population, in this study of pacemaker recipients, we found that patients with diabetes had a higher risk for HF hospitalization compared to patients without diabetes (Table 2). Diabetic cardiomyopathy is characterized by diastolic relaxation abnormalities in its early stage and later systolic dysfunction [27]. The pathophysiological mechanisms of diabetic cardiomyopathy include systemic metabolic disorders, inappropriate activation of the renin–angiotensin–aldosterone system, subcellular component abnormalities, oxidative stress, inflammation and dysfunctional immune modulation, and finally, interstitial fibrosis of cardiac tissue, which contributed to substantial cardiac stiffness with diastolic dysfunction and later, systolic dysfunction [27]. Furthermore, diabetes is an important phenotype for HF with preserved LVEF and is also an independent predictor for HF hospitalization, despite under treatments of ACEi/ARB [28]. Interestingly, the study population in this study had preserved LVEF and the administration of ACEi/ARB was higher in patients with diabetes compared to patients without diabetes before PSM (Table 1). These findings deserve further investigations regarding angiotensin receptor–neprylisin inhibitor or sodium-glucose cotransporter 2 inhibitor in patients with diabetes with preserved LVEF for PPM implantation [29, 30].

Many studies have shown that right ventricular pacing is associated with HF hospitalization [31, 32]. Our prior study showed that right ventricular pacing QRS duration ≥ 163 milliseconds increased 3.5-fold risk of HF admission, and diabetes increased 2.7-fold risk of HF hospitalization [32]. Right ventricular pacing > 50% has been reported to be associated with an increased risk of HF hospitalization [31]. In this study, after PSM, the mean percentage of right ventricular pacing did not differ between patients with diabetes and patients without diabetes (Table 1). Moreover, the distribution of patients with right ventricular pacing > 40% was similar between patient with and without diabetes before and after PSM (Table 1). Of note, patients with diabetes had a higher cumulative incidence of pacing-induced cardiomyopathy compared to patients without diabetes before and after PSM, consequently, more HF hospitalization in patients with diabetes, and these findings were consistent with our prior study [32]. Recently, conduction system pacing, such as His-bundle pacing and left bundle branch pacing, has been reported to reduce HF hospitalization compared to right ventricular pacing [33, 34]. Our study was the first to show that diabetes was an independent predictor for cardiovascular events, including HF hospitalization, in patients after right ventricular PPM implantation,
potentially related to more pacing-induced cardiomyopathy. Our findings provided the hypothesis for future studies of conduction system pacing in patients with diabetes who required PPM implantation.

4.3. Limitation. In this study, some potential limitations existed. First, although this was a retrospective single-center study, the sample size was large. Still, the potential bias inherent to nonrandomized investigations cannot be excluded. However, we performed PSM to minimize the bias between patients with and without diabetes. Second, the compliance period and dosage of prescription for beta-blocker, ACEi/ARB, diuretic agents, and statin during the follow-up period were not available in this study. Third, the duration of diagnosed diabetes before PPM implant was unknown. Finally, the preprocedural echocardiographic parameters of diastolic function by tissue Doppler or speckle-tracking imaging were not performed.

5. Conclusion

The prevalence of diabetes was over one-third of naïve PPM recipients of this cohort, and diabetes increased the risk of cardiovascular events in PPM recipients, especially for HF hospitalization.

Data Availability

The retrospective data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

The study protocol was approved by the Institutional Review Board of Chang Gung Medical Foundation (permit number: 202100907B0).

Conflicts of Interest

The authors have no conflicts of interest to disclose.

Authors’ Contributions

HCC contributed to the analysis and interpretation of data and wrote the manuscript. WHL and CHT contributed to discussion and reviewed and edited the manuscript. YLC, WCL, YNF, and SZC contributed to collection of data. MCC contributed to study design and revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgments

We appreciate the Biostatistics Center, Kaohsiung Chang Gung Memorial Hospital, for assistance with the statistical analysis.

References

[1] P. Saedi, I. Petersohn, P. Salpea et al., “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas,” Diabetes Research and Clinical Practice, vol. 157, 2019.

[2] G. Danaei, M. M. Finucane, Y. Lu et al., “National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·4 million participants,” The Lancet, vol. 378, no. 9785, pp. 31–40, 2011.

[3] C. C. Lin, C. I. Li, C. Y. Hsiao et al., “Time trend analysis of the prevalence and incidence of diagnosed type 2 diabetes among adults in Taiwan from 2000 to 2007: a population-based study,” BMC Public Health, vol. 13, p. 318, 2013.

[4] P. Z. Zimmet, D. J. Magliano, W. H. Herman, and J. E. Shaw, “Diabetes: a 21st century challenge,” The Lancet Diabetes and Endocrinology, vol. 2, no. 1, pp. 56–64, 2014.

[5] S. M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso, “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,” The New England Journal of Medicine, vol. 339, no. 4, pp. 229–234, 1998.

[6] T. Ohkuma, Y. Komorita, S. A. E. Peters, and M. Woodward, “Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals,” Diabetologia, vol. 62, no. 9, pp. 1550–1560, 2019.

[7] K. Weidner, M. Behnes, T. Schupp et al., “Increased prevalence of third-degree atrioventricular block in patients with type II diabetes mellitus,” British Medical Journal, vol. 289, no. 6459, p. 1659, 1984.

[8] B. M. Frier, “Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications,” Nature Reviews. Endocrinology, vol. 10, no. 12, pp. 711–722, 2014.

[9] T. Wasada, K. Katsumori, S. Hasumi et al., “Association of sick sinus syndrome with hyperinsulinenia and insulin resistance in patients with non-insulin-dependent diabetes mellitus: report of four cases,” Internal Medicine, vol. 34, no. 12, pp. 1174–1177, 1995.

[10] R. L. Blandford and A. C. Burden, “Abnormalities of cardiac conduction in diabetes,” British Medical Journal, vol. 289, no. 6459, p. 1659, 1984.

[11] M. R. Movahed, M. Hashemzadeh, and M. M. Jamal, “Increased prevalence of third-degree ativoventricular block in patients with type II diabetes mellitus,” Chest, vol. 128, no. 4, pp. 2611–2614, 2005.

[12] E. Rautio, F. Gadler, S. Gudbjornsdottir et al., “Patients with type 2 diabetes have an increased demand for pacemaker treatment: a comparison with age- and sex-matched control subjects from the general population,” Diabetes Care, vol. 43, no. 11, pp. 2853–2858, 2020.

[13] H. C. Chen, Y. L. Chen, B. F. Guo et al., “Thrombocytopenia, dual antiplatelet therapy, and heparin bridging strategy increase pocket hematomas complications in patients undergoing cardiac rhythm device implantation,” The Canadian Journal of Cardiology, vol. 29, no. 9, pp. 1110–1117, 2013.

[14] American Diabetes Association, “2. Classification and diagnosis of diabetes: Standards of medical care in Diabetes-2019,” Diabetes Care, vol. 42, Supplement 1, pp. S13–S28, 2019.
[15] I. H. de Boer, M. L. Caramori, J. C. N. Chan et al., “KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease,” Kidney International, vol. 98, no. 4, pp. S1–S115, 2020.

[16] A. S. Levey, L. A. Stevens, C. H. Schmid et al., “A new equation to estimate glomerular filtration rate,” Annals of Internal Medicine, vol. 150, no. 9, pp. 604–612, 2009.

[17] Y. H. Li, K. C. Ueng, J. S. Jeng et al., “2017 Taiwan lipid guidelines for high risk patients,” Journal of the Formosan Medical Association, vol. 116, pp. 217–248, 2017.

[18] H. C. Chen, M. C. Chen, Y. L. Chen, T. H. Tsai, K. L. Pan, and Y. S. Lin, “Bundled preparation of skin antisepsis decreases the risk of cardiac implantable electronic device-related infection,” Europace, vol. 18, no. 6, pp. 858–867, 2016.

[19] P. C. Austin, “Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples,” Statistics in Medicine, vol. 28, no. 25, pp. 3083–3107, 2009.

[20] A. Sinclair, P. Saeedi, A. Kaundal, S. Karuranga, B. Malanda, and R. Williams, “Diabetes and global ageing among 65-99-year-old adults: Findings from the International Diabetes Federation Diabetes Atlas, 9th edition,” Diabetes Research and Clinical Practice, vol. 162, 2020.

[21] R. Podlaha and A. Falk, “The prevalence of diabetes mellitus and other risk factors of atherosclerosis in bradycardia requiring pacemaker treatment,” Hormone and Metabolic Research Supplement, vol. 26, pp. 84–87, 1992.

[22] J. T. Lear, J. G. Lawrence, and A. C. Burden, “Prevalence of diabetes in elderly patients requiring permanent cardiac pacemaker insertion,” Acta Diabetologica, vol. 33, no. 2, pp. 169-170, 1996.

[23] M. R. Movahed, “Diabetes as a risk factor for cardiac conduction defects: a review,” Diabetes, Obesity & Metabolism, vol. 9, pp. 276–281, 2006.

[24] C. Bauters, N. Lamblin, E. P. Mc Fadden, E. Van Belle, A. Millaire, and P. de Groote, “Influence of diabetes mellitus on heart failure risk and outcome,” Cardiovascular Diabetology, vol. 2, p. 1, 2003.

[25] M. A. Cavender, P. G. Steg, S. C. Smith Jr. et al., “Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and Death,” Circulation, vol. 132, no. 10, pp. 923–931, 2015.

[26] D. K. Pasupula, A. Rajaratnam, R. Rattan et al., “Trends in hospital admissions for and readmissions after cardiac implantable electronic device procedures in the United States: an analysis from 2010 to 2014 using the National Readmission Database,” Mayo Clinic Proceedings, vol. 94, no. 4, pp. 588–598, 2019.

[27] G. Jia, A. Whaley-Connell, and J. R. Sowers, “Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease,” Diabetologia, vol. 61, no. 1, pp. 21–28, 2018.

[28] S. Lejeune, C. Roy, A. Slimani et al., “Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort,” Cardiovascular Diabetology, vol. 20, no. 1, pp. 1–12, 2021.

[29] S. D. Solomon, J. J. V. McMurray, I. S. Anand et al., “Angiotensin-nephrilysin inhibition in heart failure with preserved ejection fraction,” The New England Journal of Medicine, vol. 381, no. 17, pp. 1609–1620, 2019.

[30] S. D. Anker, J. Butler, G. Filippatos et al., “Empagliflozin in heart failure with a preserved ejection fraction,” The New England Journal of Medicine, vol. 385, pp. 1451–1461, 2021.